FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885209550> ?p ?o ?g. }

• W2885209550 endingPage "1644" @default.
• W2885209550 startingPage "1636" @default.
• W2885209550 abstract "Are pregnancy and birth rates affected by artificial oocyte activation (AOA) with SrCl2 or calcimycin after ICSI for couples with male-factor infertility linked to abnormal sperm morphology or for couples with previous ICSI cycles of unexplained low fertilization or inadequate fertilization associated with impaired oocyte morphology? AOA with either SrCl2 or calcimycin can improve the rates of clinical pregnancy, ongoing pregnancy and live birth compared with ICSI alone, and the two agents have diverse effects for different subgroups of patients. ICSI is a successful treatment for infertility, but not in all individuals. AOA has potential to overcome inadequate fertilization in ICSI. Calcimycin and SrCl2 are candidate agents for AOA, but their effectiveness remains to be compared. This study was a randomized, open-label, three-arm, parallel-group, double-centre, superiority trial conducted between April 2015 and January 2016. The study evaluated the effects of AOA with calcimycin or SrCl2 for clinical pregnancy rates after ICSI and included 343 couples divided into three groups. Couples were included if they had two previous ICSI cycles of no or low fertilization (0–30%) with unknown causes or impaired oocyte morphology. Male-factor infertility cycles (frozen–thawed sperm, surgically retrieved sperm or ejaculates contained <10 millions spermatozoa/ml) undergoing their first ICSI attempt were also included if they had 100% abnormal sperm morphology (including globozoospermia and tapered-head). Couples were randomized to undergo ICSI with SrCl2 AOA, ICSI with calcimycin AOA or ICSI alone, with clinical pregnancy as the primary endpoint. Effect sizes were summarized as absolute rate differences (ARDs) and odds ratios (ORs), with precision evaluated by 95% CIs. Both SrCl2 and calcimycin AOA improved clinical pregnancy rates compared to ICSI alone (49, 42 and 27%; ARD 22, 95% CI: 9–33; P = 0.0007 and ARD 16, 95% CI: 3–27; P = 0.014). SrCl2 and calcimycin AOA were also superior to ICSI alone on the rates of ongoing pregnancy (42, 36 and 23%; P = 0.0019 and P = 0.023) and live birth (40, 33 and 18%; P = 0.0002 and P = 0.012). Among couples with previous ICSI cycles of low fertilization, AOA with SrCl2 (but not with calcimycin) was superior to ICSI alone for rates of clinical pregnancy (ARD 35 percentage points (pp), P = 0.0007), ongoing pregnancy (ARD 27 pp, P = 0.009) and live birth (ARD 37 pp, P = 0.002). Among couples affected by male-factor infertility, AOA with calcimycin (but not with SrCl2) was superior to ICSI alone for rates of clinical pregnancy (ARD 22 pp, P = 0.006), ongoing pregnancy (ARD 19 pp, P = 0.013) and live birth (ARD 17 pp, P = 0.02). This study was an open-label trial, and this design might have introduced bias, although randomization methods were used. The study did not include a longitudinal follow-up, so further evidence is required to demonstrate the safety of AOA. The decision to use SrCl2 or calcimycin for AOA after ICSI may depend on whether the activation failure originates in the oocyte or the sperm. The study received no funding and the authors have no conflicts of interest to declare. NCT02424214. 22 April 2015. 27 April 2015." @default.
• W2885209550 created "2018-08-22" @default.
• W2885209550 creator A5001961159 @default.
• W2885209550 creator A5004026356 @default.
• W2885209550 creator A5024058249 @default.
• W2885209550 creator A5041364386 @default.
• W2885209550 creator A5071004180 @default.
• W2885209550 creator A5071550899 @default.
• W2885209550 creator A5076773089 @default.
• W2885209550 date "2018-08-07" @default.
• W2885209550 modified "2023-09-26" @default.
• W2885209550 title "Artificial oocyte activation with SrCl2 or calcimycin after ICSI improves clinical and embryological outcomes compared with ICSI alone: results of a randomized clinical trial" @default.
• W2885209550 cites W1500478148 @default.
• W2885209550 cites W1801532055 @default.
• W2885209550 cites W1963939591 @default.
• W2885209550 cites W1970482334 @default.
• W2885209550 cites W1976904579 @default.
• W2885209550 cites W1977420815 @default.
• W2885209550 cites W1982401259 @default.
• W2885209550 cites W1990602082 @default.
• W2885209550 cites W1991942108 @default.
• W2885209550 cites W1994302620 @default.
• W2885209550 cites W2006693497 @default.
• W2885209550 cites W2014697990 @default.
• W2885209550 cites W2017455102 @default.
• W2885209550 cites W2033620401 @default.
• W2885209550 cites W2047340940 @default.
• W2885209550 cites W2057657772 @default.
• W2885209550 cites W2062984300 @default.
• W2885209550 cites W2064541275 @default.
• W2885209550 cites W2066672702 @default.
• W2885209550 cites W2070640442 @default.
• W2885209550 cites W2079465654 @default.
• W2885209550 cites W2080289922 @default.
• W2885209550 cites W2082503983 @default.
• W2885209550 cites W2083433415 @default.
• W2885209550 cites W2097939257 @default.
• W2885209550 cites W2098620041 @default.
• W2885209550 cites W2099626419 @default.
• W2885209550 cites W2103732636 @default.
• W2885209550 cites W2113945113 @default.
• W2885209550 cites W2124656409 @default.
• W2885209550 cites W2125203571 @default.
• W2885209550 cites W2134305003 @default.
• W2885209550 cites W2140958036 @default.
• W2885209550 cites W2140991821 @default.
• W2885209550 cites W2143660051 @default.
• W2885209550 cites W2145981737 @default.
• W2885209550 cites W2156164053 @default.
• W2885209550 cites W2157739742 @default.
• W2885209550 cites W2165525635 @default.
• W2885209550 cites W2169240955 @default.
• W2885209550 cites W2182606439 @default.
• W2885209550 cites W2306746538 @default.
• W2885209550 cites W2315856670 @default.
• W2885209550 cites W2752062726 @default.
• W2885209550 cites W2784061244 @default.
• W2885209550 cites W4294214983 @default.
• W2885209550 doi "https://doi.org/10.1093/humrep/dey258" @default.
• W2885209550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30099496" @default.
• W2885209550 hasPublicationYear "2018" @default.
• W2885209550 type Work @default.
• W2885209550 sameAs 2885209550 @default.
• W2885209550 citedByCount "36" @default.
• W2885209550 countsByYear W28852095502019 @default.
• W2885209550 countsByYear W28852095502020 @default.
• W2885209550 countsByYear W28852095502021 @default.
• W2885209550 countsByYear W28852095502022 @default.
• W2885209550 countsByYear W28852095502023 @default.
• W2885209550 crossrefType "journal-article" @default.
• W2885209550 hasAuthorship W2885209550A5001961159 @default.
• W2885209550 hasAuthorship W2885209550A5004026356 @default.
• W2885209550 hasAuthorship W2885209550A5024058249 @default.
• W2885209550 hasAuthorship W2885209550A5041364386 @default.
• W2885209550 hasAuthorship W2885209550A5071004180 @default.
• W2885209550 hasAuthorship W2885209550A5071550899 @default.
• W2885209550 hasAuthorship W2885209550A5076773089 @default.
• W2885209550 hasConcept C105702510 @default.
• W2885209550 hasConcept C131872663 @default.
• W2885209550 hasConcept C141071460 @default.
• W2885209550 hasConcept C16685009 @default.
• W2885209550 hasConcept C168563851 @default.
• W2885209550 hasConcept C196843134 @default.
• W2885209550 hasConcept C2776537878 @default.
• W2885209550 hasConcept C2776690073 @default.
• W2885209550 hasConcept C2777688143 @default.
• W2885209550 hasConcept C2778278907 @default.
• W2885209550 hasConcept C2778279030 @default.
• W2885209550 hasConcept C2778580812 @default.
• W2885209550 hasConcept C2779234561 @default.
• W2885209550 hasConcept C2781087480 @default.
• W2885209550 hasConcept C29456083 @default.
• W2885209550 hasConcept C500014431 @default.
• W2885209550 hasConcept C512716672 @default.
• W2885209550 hasConcept C54355233 @default.
• W2885209550 hasConcept C71924100 @default.
• W2885209550 hasConcept C86803240 @default.
• W2885209550 hasConcept C88972607 @default.

• next